Satellite Bio is an early-stage tissue therapy company developing implantable satellite organs targeting liver diseases. It was founded by Catalio Venture Partner Dr. Sangeeta Bhatia at MIT.
Many liver diseases, such as urea cycle disorders, have no curative treatment aside from liver transplant, which is limited by donor organ shortages. To address this unmet need, Satellite Bio is developing technology to manufacture “satellite” allograft liver tissues, which are then implanted into patients during a surgical procedure, offloading some function from the diseased native liver. The company’s beachhead indications are two high mortality genetic liver diseases that present in infancy: OTC deficiency and Crigler-Najjar syndrome. If successful, this technology will radically transform care for patients with liver disease.